Aquestive Therapeutics Advances Non-Invasive Epinephrine Treatment
Company Announcements

Aquestive Therapeutics Advances Non-Invasive Epinephrine Treatment

Aquestive Therapeutics (AQST) has issued an update.

Aquestive Therapeutics has announced encouraging preliminary results from their study on Anaphylm™, a groundbreaking non-invasive epinephrine treatment for severe allergic reactions that could be the first of its kind if approved by the FDA. The study showed no significant difference in epinephrine absorption between self-administered and healthcare provider-administered Anaphylm, matching the rapid 15-minute median time to peak concentration. This innovative treatment could offer a life-saving alternative for allergy sufferers, with plans for a full product launch by early 2026, pending completion of ongoing clinical studies and regulatory approval.

See more insights into AQST stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAquestive Therapeutics Announces Board and Committee Changes
TipRanks Auto-Generated NewsdeskAquestive Therapeutics Advances Drug Candidates Amid Challenges
TipRanks Auto-Generated NewsdeskAquestive Therapeutics: Progress in Drug Innovation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App